Redeye: Episurf Medical Q4 - Setting the stage for 2025
Redeye provides an in-depth review of Episurf Medical’s Q4 report and events during and after the quarter. The report contained no major surprises; however, we are encouraged by the progression in the current FDA clearance process relating to Episealer MTP and the new distribution agreement with Joint Operations Ltd.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/